KV Pharmaceutical Company Reports Fiscal 2009 First Quart...(hatmore than 37 million women in the Uni...),Health

Date:8/11/2008

hat more than 37 million women in the United States are at or near the age of menopause and 45.5 million women are post-menopausal. About three-fourths of women transitioning into menopause will experience some degree of symptoms associated with menopause, with 40-60% of these women suffering from moderate-to-severe vasomotor symptoms.

The Company believes that Evamist(TM) will be a significant contributor to Ther-Rx net revenues during the second half of fiscal 2009.

See section below entitled "About Evamist(TM)", and "About Estrogen Therapy" including Black Box information, for important safety information relating to the prescription and use of Evamist(TM).

Anti-Infective Products

Net sales of Clindesse(R) increased 9.5% to $5.0 million for the quarter, compared to $4.6 million in the first quarter of fiscal 2008 due to improved market share and the impact of price increases.

Clindesse(R), indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women, continues to experience growing prescription trends in the anti-infective category. Currently, Clindesse(R) carries a 27.5% market share, compared to 26.3% from the first quarter of the previous fiscal year, higher than all other clindamycin-based intravaginal BV products combined.

Oral Iron Supplement Products

The $1.3 million, or 16.5%, increase in net sales of our hematinic products to $9.1 million for the quarter resulted primarily from sales volume growth of Repliva 21/7(R) coupled with price increases on our other hematinic products.

Repliva 21/7(R) continues to be the fastest growing product in the oral prescription iron supplements category. This product is uniquely formulated to provide efficient absorption with clinically proven results. The benefits of this product are driven by a proprietary formulation of elemental iron, two absorption promoters and a scientifically designed dosing regimen all designed to help promote maximum iron a
'/>"/>

SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance